Month: May 2022

-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22– -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States-Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange                GENEVA, Switzerland – May 17, 2022 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the first quarter...

VANCOUVER, British Columbia, May 17, 2022 (GLOBE NEWSWIRE) — Pure Gold Mining Inc. (TSX-V:PGM, LSE:PUR) (“PureGold” or the “Company”), reports its first quarter 2022 summary financial and operating results. The Company’s interim financial statements and related management’s discussion and analysis for the three months ended March 31, 2022, will be available for download on SEDAR and on the Company’s website. All amounts are expressed in Canadian dollars (“$”), unless otherwise noted). A summary of the highlights for the three months ended March 31, 2022, and subsequent to date for the Company and its 100% owned PureGold Mine Project (“PureGold Mine”) or the “Project”) are as follows: Gold ProductionGold production for the quarter ended March 31, 2022 was 6,653 ounces Gold sold for the quarter ended March 31, 2022 was 7,876 ouncesProcessingFor...

DENVER, May 16, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a business update for the first quarter of 2022.  “Our team had an extremely productive first quarter,” said Mydecine CEO Josh Bartch. “Management has been working diligently to decrease expenses and increase efficiencies, setting Mydecine up for future success. On the heels of Mydecine’s positive pre-Investigational New Drug Application (“IND”) meeting with the FDA and a conditional Institutional Review Board (“IRB”) approval, we are excited, and working towards submitting our full IND and breakthrough therapy applications...

Investments In Transformation Continue-Expected to Begin Driving Revenue Growth in 2Q 2022 FAIRFAX, Va., May 16, 2022 (GLOBE NEWSWIRE) — WaveDancer (NASDAQ: WAVD), today reported its results for the first quarter ended March 31, 2022, which was characterized by continued investment in the WaveDancer’s software development and sales team. This included new hires, board appointments, partnerships, and a definitive acquisition agreement as WaveDancer strives to become a leader in the zero trust, blockchain, and secure supply chain market. WaveDancer CEO Jamie Benoit commented, “Our first quarter 2022 saw the company continue to prioritize investments in key operational areas.   In addition to the recent additions, we have made at the board and senior leadership levels, we have also added three new blockchain sales professionals as...

BERLIN, MD, May 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Calvin B. Taylor Bankshares, Inc. (the “Company”) (OTCQX: TYCB), parent company of Calvin B. Taylor Bank, today reported net income of $2.29 million for the first quarter ended March 31, 2022 (“1Q22”), as compared to $2.60 million for the first quarter ended March 31, 2021 (“1Q21”) and $2.14 million for the fourth quarter ended December 31, 2021 (“4Q21”).  President and Chief Executive Officer Raymond M. Thompson remarked, “The Company experienced strong commercial and residential organic loan growth in 1Q22 as borrowers moved to consummate credit needs ahead of a forecasted, and realized, Federal Reserve interest rate increase during the quarter.  The Federal Reserve’s March 2022 rate increase constituted the first interest rate increase since December 2018.  The Company’s...

Cash on hand was $8,327,812 as at March 31, 2022, up 7,309% compared to $112,397 as at December 31, 2021. Cash provided by operating activities was $8,211,415 in the three months ending March 31, 2022, compared to cash used by operating activities of $4,382,478 in the prior three months ending March 31, 2021. Revenue was $16,693,947 in the three months ending March 31, 2022, up 48%, compared to $11,248,001 over the prior three months ending March 31, 2021. Gross profit was $6,409,277 in the three months ending March 31, 2022, up 518%, compared to $1,053,888 over the prior three months ending March 31, 2021. Net loss was $1,436,609 in the three months ending March 31, 2022, an improvement of 86%, compared to $9,960,138 over the prior three months ending March 31, 2021.TORONTO, May 16, 2022 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”...